Dr. Arash Mohebati, MD

Dr. Mohebati practices at Concord Medical Center in Concord, California, part of John Muir Health.

Dr. Mohebati's NPI, 1467611244, was assigned on June 5, 2008. Dr. Mohebati graduated from Rutgers Robert Wood Johnson Medical School in 2004. Dr. Mohebati's New Jersey license number on file is 25MA08342500.

Dr. Mohebati's primary practice is Concord Medical Center, at 2540 East St, Concord, CA 94520 in Contra Costa County. The practice phone is (925) 682-8200.

Dr. Mohebati's primary practice is Concord Medical Center in Concord, California, part of John Muir Health. Dr. Mohebati is also affiliated with John Muir Medical Center, Walnut Creek. The medical group on file is John Muir Health. Dmand AI also links Dr. Mohebati to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mohebati practices, 5 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Mohebati's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Mohebati is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Mohebati's licenses on file in 3 states: New Jersey, California and New York.

Dmand AI lists removal of damaged skin or skin graft and thyroid surgery among the conditions Dr. Mohebati treats.

CMS data shows 644 Medicare services from Dr. Mohebati across 10 procedure codes in 2024, for 220 Medicare patients. Medicare paid $62,938 for them.

CMS counts 220 Medicare patients who saw Dr. Mohebati in 2024. The largest group is 65 to 74, with 110 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mohebati's median patient age at 63, with 69% women.

In 2024, Dr. Mohebati wrote 79 Medicare Part D claims for 56 patients. 95% of them were for generic drugs. CMS names the drug for 62 of them, across 2 drugs with 11 or more claims each, at $135 in total drug cost. In 2023, CMS named 67 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Mohebati for performance year 2024, reported as part of a group. Dr. Mohebati accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mohebati as offering telehealth. CMS counts 19 procedures of melanoma (skin cancer) excision by Dr. Mohebati, more than 74% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Mohebati, published from 2005 to 2014. 2012 was the busiest year, with 3. The most frequent topics are Cyclooxygenase 2, Prostaglandins and Smoking. Dr. Mohebati has published most often in Ann Surg Oncol. Dr. Mohebati's most frequent co-authors are Ashok R. Shaha, MD, Andrew J. Dannenberg, MD and Jatin P. Shah, MD.

CMS Open Payments shows 24 general payments to Dr. Mohebati from 14 drug and device companies from 2016 to 2025. Education make up the largest share, 82% of the total. Acell, Inc. paid the most, $4,494.

Dmand AI lists 2 awards for Dr. Mohebati, most recently CMS Stage 1 EHR in 2013.

Dr. Mohebati graduated from Rutgers Robert Wood Johnson Medical School in 2004. Dr. Mohebati is a member of ACS.

Dr. Mohebati is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.